Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02756208 · ClinicalTrials.gov registry record · Phase 1
A Safety and Immunogenicity Trial of IHV01
A Phase 1 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT02756208 is a Phase 1 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 65 participants.
The verdict
NCT02756208, a Phase 1 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety of the FLSC vaccine and will be a randomized, placebo-controlled, modified double-blinded dose escalation study in 60 healthy adult volunteers (Human Immunodeficiency Virus-1 uninfected).
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL 300 ug FLSC vaccine
- BIOLOGICAL 150 ug FLSC vaccine
- BIOLOGICAL 75 ug FLSC vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2015-11 |
| Est. Completion | 2018-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02756208
The ClinicalTrials.gov registry entry for NCT02756208 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02756208 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02756208 about?
NCT02756208 is a clinical study titled "A Safety and Immunogenicity Trial of IHV01". This study is designed to evaluate the safety of the FLSC vaccine and will be a randomized, placebo-controlled, modified double-blinded dose escalation study in 60 healthy adult volunteers (Human Immunodeficiency Virus-1 uninfected).
What is the current status of trial NCT02756208?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2015-11. Estimated completion is 2018-07.
What interventions are being tested in trial NCT02756208?
The interventions under investigation include: Placebo (BIOLOGICAL), 300 ug FLSC vaccine (BIOLOGICAL), 150 ug FLSC vaccine (BIOLOGICAL), 75 ug FLSC vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02756208?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.